[18F]RCCB6 PET/CT in Diagnosing Clear-Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging.
Cancer DiscovOct 1, 2026
Qianyun Wu, Shuxian An, Fabrizia Gelardi et al.
✦ AI-curated · Sources linked
In 30 seconds
[18F]RCCB6 PET/CT was evaluated in a single-center phase II trial for detecting metastases in clear-cell renal cell carcinoma (ccRCC). Among 150 patients, it demonstrated a sensitivity of 94.2% and significantly outperformed [18F]FDG PET/CT with a sensitivity of 90.5% compared to 41.1%. The imaging findings altered clinical management in 58.7% of patients.
Key findings
- [18F]RCCB6 PET/CT achieved 94.2% sensitivity and 80% specificity in detecting ccRCC metastases.
- [18F]RCCB6 PET/CT outperformed [18F]FDG PET/CT with a sensitivity of 90.5% vs. 41.1%.
- The imaging findings changed clinical management in 58.7% of patients.
- [18F]RCCB6 uptake correlated strongly with CD70 expression (r = 0.843).
Why it matters
The study highlights the potential of [18F]RCCB6 PET/CT as a superior imaging modality for diagnosing metastatic ccRCC, which could lead to more accurate treatment decisions and improved patient outcomes.